3 ms·
Will it reinfect persons who has already been infected? If not then hers immunity will happen eventually. Maybe it will not be pretty to get there.
by hosteur 5y ago
Will it reinfect persons who has already been infected?
If not then hers immunity will happen eventually.
Maybe it will not be pretty to get there.
- ajsnigrutin 5y agoDepends... Young people get over it pretty fast and mostly without issues, especially vaccinated ones. In slovenia, we've been closing down schools, and letting people get infected and die in old-age homes, instead of keeping schools open (atleast partially) and doing more to protect the people who actually need protection (like ventilation, better isolation, etc.) We've had around 4400 deaths by now (2 mio population) with some estimates of 800k+ people having it (260k confirmed cases), and we've had 5 deaths in <35yo age group, and we count every death after 28days of positive test as a covid death.
- belter 5y agoDoes than mean if somebody dies in a car accident, 28 days after a positive test, is counted as a covid death ?
- ajsnigrutin 5y agoYep. if((now()-positivetestdate())<28days && person==dead) { coviddeaths++; } Also suicide (our media has been told to 'carefully' report about suicide, and we still don't have the 2020 suicide statistics available).
- criticaltinker 5y ago> Will it reinfect persons who has already been infected? At present time, a number of studies show that reinfection in people with naturally acquired immunity is relatively rare (see supporting excerpts below). That said, the delta variant (and most other variants of concern) have mutations that confer partial immune escape . We can expect that such variants will pose an increasing risk to both the vaccinated & naturally immune. [5][6][7] The virus can mutate faster than the scientific literature can establish consensus - I suppose we'll be facing a degree of uncertainly for a while to come. > "A previous history of SARS-CoV-2 infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection. This study shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals." [1] > "Reinfection is rare in the young and international population of Qatar. Natural infection appears to elicit strong protection against reinfection with an efficacy ~95% for at least seven months." [2] > "To our knowledge, this is the first systematic review to synthesise the evidence on the risk of SARS‐CoV‐2 reinfection over time. [...] Reinfection was an uncommon event (absolute rate 0%–1.1%), with no study reporting an increase in the risk of reinfection over time. [...] These data suggest that naturally acquired SARS‐CoV‐2 immunity does not wane for at least 10 months post‐infection. However, the applicability of these studies to new variants or to vaccine‐induced immunity remains uncertain." [3] > "Cumulative incidence of COVID-19 was examined among 52238 employees in an American healthcare system. COVID-19 did not occur in anyone over the five months of the study among 2579 individuals previously infected with COVID-19, including 1359 who did not take the vaccine. [...] Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before." [4] [1] SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040523/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040523/ [2] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy https://pubmed.ncbi.nlm.nih.gov/33937733/ https://pubmed.ncbi.nlm.nih.gov/33937733/ [3] Quantifying the risk of SARS‐CoV‐2 reinfection over time https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209951/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209951/ [4] Necessity of COVID-19 vaccination in previously infected individuals https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3.full.pdf https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v... [5] SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern https://science.sciencemag.org/content/early/2021/06/30/science.abi7994 https://science.sciencemag.org/content/early/2021/06/30/scie... [6] mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants https://www.nature.com/articles/s41586-021-03324-6 https://www.nature.com/articles/s41586-021-03324-6 [7] Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization https://www.nature.com/articles/s41586-021-03777-9 https://www.nature.com/articles/s41586-021-03777-9